Collectively, these observations demonstrate that the hyperglycemic phenotypes in HFD-fed and db/db mice can be alleviated by downregulating Sam68 expression in the liver and, consequently, that Sam68 may be a therapeutic target for the treatment of T2D. This evidence concerns the gene KHDRBS1 and type 2 diabetes mellitus.